Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Brain-derived neurotrophic factor (BDNF), a neurotrophin that regulates neuronal function and development, is implicated in several neurodegenerative conditions. Preliminary data suggest that a reduction of BDNF concentrations may lead to postchemotherapy cognitive impairment. We hypothesized that a single nucleotide polymorphism (rs6265) of the BDNF gene may predispose patients to cognitive impairment. This study aimed to evaluate the effect of BDNF gene polymorphism on chemotherapy-associated cognitive impairment. METHODS: Overall, 145 patients receiving chemotherapy for early-stage breast cancer (mean age: 50.8 ± 8.8 y; 82.1% Chinese) were recruited. Patients' cognitive functions were assessed longitudinally using the validated Functional Assessment of Cancer Therapy-Cognitive Function (v.3) and an objective computerized tool, Headminder. Genotyping was performed using Sanger sequencing. Logistic regression was used to evaluate the association between BDNF Val66Met polymorphism and cognition after adjusting for ethnicity and clinically important covariates. RESULTS: Of the 145 patients, 54 (37%) reported cognitive impairment postchemotherapy. The Met/Met genotype was associated with statistically significant lower odds of developing cognitive impairment (odds ratio [OR] = 0.26; 95% CI: 0.08-0.92; P = .036). The Met carriers were less likely to experience impairment in the domains of verbal fluency (OR = 0.34; 95% CI: 0.12-0.90; P = .031) and multitasking ability (OR = 0.37; 95% CI: 0.15-0.91; P = .030) compared with the Val/Val homozygote. No associations were observed between Headminder and the BDNF Val66Met polymorphism. CONCLUSIONS: This is the first study to provide evidence that carriers of the BDNF Met allele are protected against chemotherapy-associated cognitive impairment. Further studies are required to validate the findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888
Hariri, A. R., Goldberg, T. E., Mattay, V. S., Kolachana, B. S., Callicott, J. H., Egan, M. F., & Weinberger, D. R. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06690.2003 · Cited by 1,045 · cited 1×
“In the context of human cognition, initial genetic association studies showed that the Met allele was associated with reduced memory performance in populations of healthy young individuals and schizophrenic patients.(24) – 26 However, it is important to emphasize that these studies possess major limitations.”
BackgroundLittle, J., Higgins, J. P. T., Ioannidis, J. P. A., Moher, D., Gagnon, F., von Elm, E., Khoury, M. J., Cohen, B., Davey-Smith, G., Grimshaw, J., et al. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000022 · Cited by 811
Oxidative stress and apoptosis: Impact on cancer therapy
Ozben, T. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20874 · Cited by 751 · cited 1×
“Chemotherapeutic agents have been well established to generate reactive oxygen species in patients during systemic cancer treatment.(33) For example, doxorubicin mediates neurotoxicity in the brain indirectly by stimulating production of tumor necrosis factor–a, which triggers the synthesis of inflammatory cytokines t…”
BackgroundGratacòs, M., González, J. R., Mercader, J. M., de Cid, R., Urretavizcaya, M., & Estivill, X. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.025 · Cited by 428
Hind, D., Cotter, J., Thake, A., Bradburn, M., Cooper, C., Isaac, C., & House, A. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-5 · Cited by 180
Cited by
Lange, M., Joly, F., Vardy, J., Ahles, T., Dubois, M., Tron, L., Winocur, G., De Ruiter, M. B., & Castel, H. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz410 · Cited by 667
Cognitive Effects of Cancer and Cancer Treatments
Ahles, T. A., & Root, J. C. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084903 · Cited by 367
Loss of adaptive myelination contributes to methotrexate chemotherapy-related cognitive impairment
Geraghty, A. C., Gibson, E. M., Ghanem, R. A., Greene, J. J., Ocampo, A., Goldstein, A. K., Ni, L., Yang, T., Marton, R. M., Paşca, S. P., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.04.032 · Cited by 288
Mechanisms of Chemotherapy-Induced Neurotoxicity
Was, H., Borkowska, A., Bagues, A., Tu, L., Liu, J. Y. H., Lu, Z., Rudd, J. A., Nurgali, K., & Abalo, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.750507 · Cited by 285
Metadata
- Authors
- Ng, T., Teo, S. M., Yeo, H. L., Shwe, M., Gan, Y. X., Cheung, Y. T., Foo, K. M., Cham, M. T., Lee, J. A., Tan, Y. P., Fan, G., Yong, W. S., Preetha, M., Loh, W.-J. K., Koo, S.-L., Jain, A., Lee, G. E., Wong, M., Dent, R., Yap, Y. S., Ng, R., Khor, C. C., Ho, H. K., & Chan, A.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-08-19
- Volume
- 18
- Issue
- 2
- Pages
- 244-251
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2268447844
- Cited by
- 100
- References
- 7
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. https://app.cochat.ai/papers/10.1093/neuonc/nov162
- The paper
- Ng, T., Teo, S. M., Yeo, H. L., Shwe, M., Gan, Y. X., Cheung, Y. T., Foo, K. M., Cham, M. T., Lee, J. A., Tan, Y. P., Fan, G., Yong, W. S., Preetha, M., Loh, W.-J. K., Koo, S.-L., Jain, A., Lee, G. E., Wong, M., Dent, R., . . . Chan, A. (2016). Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. Neuro-Oncology. https://doi.org/10.1093/neuonc/nov162
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.